AcquisitionOther
Neuphoria Therapeutics Inc. acquired Neuphoria. Upon completion of the Transaction, the combined company plans to operate
Public M&A record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Neuphoria Therapeutics Inc. -> Neuphoria. Upon completion of the Transaction, the combined company plans to operate · $89 million
Strategic Rationale for the Merger and Financing Scancell's lead asset, iSCIB1+, has a defined regulatory path with fast-track designation from the US Food and Drug Administration and continues to demonstrate a potent and durable efficacy of 77 per cent Progre
Open source record (SEC) ↗